Spinout Active LTD

Company profile

Omecu Limited

OMECU | Genomics Analysis Platform

OMECU is a powerful genomics analysis software platform. Interactively query multiple genomics data sets securely and get answers in seconds.

CRN
SC695247
Founded
2021
Age
5

Overview

Browse spinouts
Legal name
OMECU LIMITED
Region
Unknown
Registered address
144 ST VINCENT STREET
C/O MCKEE CAMPBELL MORRISON
GLASGOW
UNITED KINGDOM
G2 5LQ
Insolvency history
No

Company events

Reference milestones and recent Companies House filing stream events.

5 events
19 Apr
2027

Confirmation statement due

Confirmation Due

Next confirmation statement due date

31 Jan
2027

Accounts due

Accounts Due

Next accounts due date

05 Apr
2026

Confirmation statement filed

Confirmation

Last confirmation statement made up date

30 Apr
2025

Accounts filed

Accounts

Last accounts made up date

09 Apr
2021

Incorporated

Inception

Company registered at Companies House

Spinout profile

9 entries

Company description

Omecu develops a cloud-based platform for the analysis of large-scale genetic and epidemiologic datasets, with the aim of democratising genome data.

Software development for analysis of big data.

Business and domestic software development Aims to democratise genetic data access and cut from days to minutes the time it takes to analyse millions of genetic records. Wide-ranging benefits in drug discovery and personalised medicine, while improving patient data security.

Project impact

Received support from the Wellcome iTPA programme, participated in the SETSquared ICURe programme, and received Medical Research Council grants. They also received funding from the University's Data-Driven Entrepreneurship Seed Fund and Fast Track Mentor initiatives, supported by the Scottish Funding Council.

It has been created recently.

Company is new and no impacts to date

Omecu
2021
Omecu
2021
Omecu
2021
Omecu
2021
Omecu
2021
Omecu
2021
Omecu
2021
OMECU LIMITED
2021
Omecu Ltd
2021

Public funding

1 award
First funded
2021
Funded years
2021
Age at first award
0 years

Projects

2021 Study Lead participant

Golem: A disruptive platform to access and interactively analyse genetic data

1 Oct 2021 to 31 Dec 2022

Awarded
£288,694
Total cost £288,694

Being able to extract useful information from genetic and health data is a key challenge for the next decade. Human genomic data is doubling in size every seven months and may soon exceed other Big Data generators such as astronomy, YouTube and Twitter. Although this data is revolutionising medicine and development of new therapeutics and diagnostics, rea...

Product types

Study